Correlation of Apgar Score with Asphyxial Hepatic Injury and Mortality in Newborns: A Prospective Observational Study From India

Deepak Sharma¹, Mukesh Choudhary², Mamta Lamba³ and Sweta Shastri⁴

¹Department of Pediatrics, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India. ²Department of Medical and Paediatric Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India. ³Department of Microbiology, SMS Medical College, Jaipur, Rajasthan, India. ⁴Department of Pathology, N.K.P. Salve Medical College, Nagpur, Maharashtra, India.

ABSTRACT
OBJECTIVE: The objective of this study is to determine the correlation of Apgar score with asphyxial hepatic injury and neonatal mortality in moderately and severely asphyxiated newborns.

MATERIAL AND METHODS: This is a secondary analysis of our prospective observational case-controlled study. Sixteen neonates with severe birth asphyxia (five-minute Apgar ≤ 3) were compared with either 54 moderate asphyxia neonates (five-minute Apgar >3) or 30 normal neonates. Liver function tests were measured on postnatal days 1, 3, and 10 in the study and control groups. Neonatal mortality was observed in the study and control population.

RESULTS: Correlation of Apgar score in severely asphyxiated neonates compared with normal Apgar score neonates and moderately asphyxiated neonates for deranged hepatic function showed significant correlation (odds ratio [OR] 4.88, 95% CI 3.26–5.84, P = 0.01 and OR 2.46, 95% CI 1.94–3.32, P = 0.02, respectively). There was a significant increase in serum lactate dehydrogenase (LDH) and total bilirubin on day 1 and serum LDH at age of 10th postnatal life in severely asphyxiated neonates when compared to moderately asphyxiated neonates, whereas there was a significant decrease in total bilirubin and serum albumin on day 3 in severely asphyxiated neonates. There was a significant increase in serum alanine transaminase, serum LDH, and total bilirubin on day 1, serum aspartate transaminase, serum LDH, and total bilirubin on day 3, and International Normalized Ratio on day 10 of postnatal life when severely asphyxiated neonates were compared with normal neonates. There was a significant reduction in total protein and serum albumin on day 1 and direct bilirubin on day 3 in severely asphyxiated neonates when compared with normal neonates. There was a significant increase in neonatal mortality in severely asphyxiated neonates when compared to the other two groups. Correlation of Apgar score in severely asphyxiated neonates compared with normal Apgar score neonates and moderately asphyxiated neonates for neonatal mortality showed significant correlation (odds ratio [OR] 2.23, 95% CI 1.42–3.04, P = 0.03 and OR 1.87, 95% CI 1.64–2.02, P = 0.04, respectively).

CONCLUSION: The severity of hepatic dysfunction correlates well with increasing severity of asphyxia. The neonatal mortality also showed good correlation with Apgar score in our study, although we need a large multicentric trial to confirm our observations. Apgar score combined with hepatic dysfunction can be used as a prognostication marker for neonatal mortality.

KEYWORDS: severe birth asphyxia, moderate birth asphyxia, five-minute Apgar score, hepatic dysfunction, neonatal mortality

CITATION: Sharma et al. Correlation of Apgar Score with Asphyxial Hepatic Injury and Mortality in Newborns: A Prospective Observational Study From India. Clinical Medicine Insights: Pediatrics 2016:10 27–34 doi: 10.4137/CMPed.S38503.

TYPE: Original Research
RECEIVED: January 07, 2016. RESUBMITTED: March 28, 2016. ACCEPTED FOR PUBLICATION: April 05, 2016.
ACADEMIC EDITOR: Praveen Kumar, Editor in Chief
PEER REVIEW: Four peer reviewers contributed to the peer review report. Reviewers’ reports totaled 1477 words, excluding any confidential comments to the academic editor.
FUNDING: Authors disclose no external funding sources.
COMPETING INTERESTS: Authors disclose no potential conflicts of interest.
CORRESPONDENCE: mukeshchoudharydm@gmail.com

COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

Introduction
A recent study published in Lancet reported that around 6.3 million children died before reaching age of five years in 2013, out of which 51.8% died of infectious causes and 44% died in the neonatal period. The most common causes of neonatal deaths were preterm birth complications, birth asphyxia, neonatal sepsis or meningitis, or other infections.¹ There are many interventions that have been implemented to decrease neonatal mortality and sepsis.²⁻⁹ The majority of the neonatal deaths (99%) occur in low- and middle-income countries, out of which more than 50% neonatal deaths occur at homes, which lack adequate care.¹⁰,¹¹ The neonates of developing countries have intrauterine growth restriction too, which makes them further vulnerable to various neonatal morbidities and mortality.¹²⁻¹⁴ In the past two decades, there has been a significant reduction in under-five mortality, but there has been relatively little change in newborn mortality.¹⁵ The neonatal mortality because of sepsis is attributed to multidrug-resistant organisms, and sepsis in these neonates can be either early onset or late onset.¹⁶,¹⁷

Perinatal asphyxia is one of the leading causes of neonatal mortality in developing countries such as India¹⁵,¹⁸ when compared to perinatal asphyxia being cause of neonatal mortality in developed countries.¹⁹ In addition, perinatal asphyxia causes an even more number of children to develop neurological sequelae. The clinical signs following perinatal asphyxia...
have been called hypoxic–ischemic encephalopathy (HIE). HIE is multisystem involvement such as brain (seizures both clinical and electroencephalography [EEG] proven, neonatal encephalopathy, stupor, and coma),20 renal,21 hepatic, cardiovascular, pulmonary, and hematological,22,23 although isolated nervous system involvement is also seen.24 Various biochemical markers have been used to find out organ dysfunction.25 The standard definition of perinatal hypoxia as described by the AAP includes when a neonate demonstrates all of the following: (a) profound metabolic or mixed acidemia (pH <7.00) on an umbilical arterial blood sample, if obtained, (b) an Apgar score of 0–3 for longer than five minutes, (c) neurologic manifestation, EEG, seizure, coma, or hypotonia, and (d) evidence of multiorgan dysfunction.26 The other criteria that have defined asphyxia and have included HIE as a cause of neonatal encephalopathy include (a) prolonged (>1 hour) antenatal acidosis, (b) fetal heart rate less than 60 beats/min, (c) Apgar score ≤5 at ≤10 minutes, (d) need for positive pressure ventilation for >1 minute or first cry delayed for >5 minutes, (e) seizures within 12–24 hours of birth, and (f) burst suppression or suppressed background pattern on EEG or amplitude integrated EEG.27 Hepatic dysfunction is usually seen in these asphyxiated newborns as liver is the site of innumerable metabolic processes. There is usually an early, abrupt, and transient (within 24–72 hours after) increase in various hepatic enzymes, namely aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH). Usually, this increase returns to baseline within 10 days after birth.28 A recent study published in Lancet showed the importance of five-minute Apgar score in neonatal mortality and proved the role of Apgar score in predicting neonatal mortality.29 There has not been any trial that has seen the correlation between five-minute Apgar score with hepatic dysfunction and neonatal mortality in these asphyxiated newborns; hence, we conducted this secondary analysis of our study to determine this correlation.

Material and Methods

This is a secondary analysis of our study, in which we have compared and correlated the hepatic dysfunction on the basis of five-minute Apgar score in newborns with severe asphyxia with newborns with moderate asphyxia and normal control neonates.30 We also compared the five-minute Apgar score correlation with neonatal mortality in severely and moderately asphyxiated neonates.

This prospective observational case-controlled study was conducted in the neonatal intensive care unit of Umaid Hospital, Tertiary care hospital in Jodhpur, India, over a period from January 2011 to December 2011. The study was approved by the institutional research board (IRB) of S.N.Medical College, Jodhpur, Rajasthan, India. A convenient sample of 100 full-term intramural neonates (retrospective data of last one year regarding intramural neonates with moderate and severe asphyxia were analyzed) was taken. These neonates were enrolled in the study after taking written parental consent.

The study population had two groups, study group A (case) comprised 70 newborns, suffering from birth asphyxia, ie, an Apgar score of 7 or less at five minutes, while control arm (group B) had 30 healthy newborns with Apgar score more than 7 at five minutes. Neonates were further sorted according to Apgar score at five minutes as mild (6 and 7), moderate (4 and 5), or severe (3 or less) and graded into HIE stages by the Sarnath and Sarnath staging system.31 The exclusion criteria included neonates having a congenital malformation or a primary disease of liver or bacterial sepsis or receiving potentially hepatotoxic drug therapy.

Full medical history, including perinatal history, especially the history of anesthesia during cesarean section and drug intake by mother or infant with detail clinical and neurologi- cal examination laying stress on abdominal examination with the exception of newborns with liver disease or neonatal sep sis, were noted. All biochemical parameters of liver function, ie, the serum ALT (normal value 6–50 U/L), AST (normal value 35–140 U/L), ALP (normal value 150–400 U/L), LDH (normal value 160–450 U/L), total protein (normal value 4.5–8.4 g/dL), serum albumin (normal value 2.5–3.6 g/dL), bilirubin (total and direct; normal value <2 mg/dL), prothrombin time (PT; normal value 10–16.2 seconds), and International Normalized Ratio (INR; normal value 1.1–1.2) were measured postnatal days 1, 3, and 10 in both study and control groups. Normal cutoff values were taken as per neonatal reference normogram. Liver was observed for congenital malformation or abnormality of biliary tract within 24 hours of birth by an ultrasound. Newborn infants who developed liver dysfunction were managed conservatively as per the standard hospital protocol. The management of asphyxiated neonates involved monitoring of seizure and also maintenance of normal metabolic milieu, including glucose, serum electrolytes, acidosis, pH, and calcium. The neonate shock was managed with vasopressors, and target was blood pressure at 50 centile as per gestational age.32 The neonatal seizures were managed with phenobarbitone (maximum loading of 20 mg/kg and minimum loading of 10 mg/kg followed by maintenance dose of 3–5 mg/kg/day) and Phenytin (maximum loading of 20 mg/kg and maintenance dose of 5–8 mg per kg/day) as second line of anticonvulsants. Anticonvulsants were started after ruling out any metabolic abnormality. Any neonate with severe respiratory distress and respiratory failure was given invasive ventilation as per the unit policy. All neonates underwent head ultrasound at the time of discharge. The criteria for liver impairment were ALT >50 U/L, AST >140 U/L, ALP >420 U/L, LDH >580 U/L, total protein <4.5 g/dL, serum albumin <2.5 g/dL, PT >20 seconds, and INR >1.2.

Statistical calculation. All the data were entered in Microsoft excel sheet, and statistical analysis was executed using SPSS version 21 for windows. The asphyxiated newborns with five-minute Apgar score less than 3 (severe asphyxia) were compared with moderate asphyxiated newborns with Apgar score (4 and 5) and also with normal neonates (>7) that acted as control. Various liver function tests (ALT,
Correlation of Apgar score with asphyxial hepatic injury in newborns

AST, LDH, ALP, PT, INR, serum albumin, total bilirubin, and direct bilirubin) and neonatal mortality were compared between each group. Student’s t-test and chi-square test were done for analysis. P value less than 0.05 was considered statistically significant. To correlate the severity of asphyxia based on Apgar score with LFTs and mortality, multivariate coefficient of correlation was calculated. This research complied with the principles of the Declaration of Helsinki.

Results
Out of 70 asphyxiated newborns, 16 newborns had severe birth asphyxia and remaining had moderate birth asphyxia. Thirty healthy newborns with normal Apgar score acted as control.

The mean weight of neonates in severe asphyxia group was 2.90 ± 0.34 kg, which was not statistically significant compared with neonates with moderate asphyxia (3.06 ± 0.36 kg) and also when compared with normal neonates (2.90 ± 0.30 kg).

The mean gestational age in severe asphyxia group was 38.02 ± 0.8 weeks, whereas the mean gestational age in the moderate asphyxia and control group was 38.60 ± 0.6 weeks and 38.52 ± 0.5 weeks, respectively (P > 0.1). The mean cord pH in severe asphyxia group was 6.86 ± 0.02 and in moderate asphyxia it was 6.98 ± 0.02.

On comparing the various liver function tests between severely asphyxiated newborns (five-minute Apgar score ≤3) versus newborns with moderate asphyxia (five-minute Apgar score 4 and 5), at age of first day, third day, and tenth day, there was significant increase in serum LDH (Fig. 1) and total bilirubin on day 1 with other liver function test being not significantly deranged. On day 3, there was significant decrease in total bilirubin and serum albumin (Fig. 2) and there was trend toward significant decrease in direct bilirubin level. At age of 10 days, there was significant increase in serum LDH level (Fig. 1; Table 1).

The comparison of various liver function tests between newborns with Apgar score ≤3 (severe asphyxia) versus normal control newborns at age of one, three, and tenth postnatal life showed that on day 1, there was significant increase in serum ALT (Fig. 3), serum LDH (Fig. 1), and total bilirubin, whereas there was significant reduction in total protein and serum albumin (Fig. 2). At postnatal age of three days, there was significant increase in serum AST (Fig. 3), serum LDH (Fig. 1), and total bilirubin and also there was significant reduction in direct bilirubin. At age of day 10, there was a significant difference in only INR that showed increased INR in severely asphyxiated neonates (Fig. 4; Table 1).

There was a significant increase in neonatal mortality in neonates with severe asphyxia in comparison to moderate asphyxia neonates and normal Apgar neonates (Table 1). Correlation of Apgar score in severely asphyxiated neonates compared with normal Apgar score neonates and moderately asphyxiated neonates for neonatal mortality showed significant correlation (odds ratio [OR] 2.23, 95% CI 1.42–3.04, P = 0.03 and OR 1.87, 95% CI 1.64–2.02, P = 0.04, respectively). Correlation of Apgar score in severely asphyxiated neonates compared with normal Apgar score neonates and moderately asphyxiated neonates for deranged hepatic function showed significant correlation (OR 4.88, 95% CI 3.26–5.84, P = 0.01 and OR 2.46, 95% CI 1.94–3.32, P = 0.02, respectively).

Discussion
Perinatal asphyxia is an insult to the fetus or the newborn due to lack of oxygen and/or lack of perfusion to various organs of the body. Neonatal birth asphyxia is a multisystem disorder

![Figure 1. Comparison of serum lactate dehydrogenase (LDH) in neonates with severe asphyxia, with moderate asphyxia, and severe asphyxia with normal control (*significant difference between I and II and #significant difference between I and III).](image-url)
The aim of present study was to evaluate the severity of hepatic injury in newborns with severe asphyxia and moderate asphyxia, and severe asphyxia and normal neonates at age of first day, third day and tenth day.

|          | NEONATES WITH APGAR SCORE 3 AT 5 MINUTES (SEVERE ASPHYXIA) | NEONATES WITH APGAR SCORE 4 AND 5 AT 5 MINUTES (MODERATE ASPHYXIA) | NEONATES WITH APGAR SCORE MORE THAN 7 AT 5 MINUTES (CONTROL) | P-VALUE I VS II | P-VALUE I VS III |
|----------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|----------------|----------------|
| Weight   | 2.90 ± 0.34                                    | 3.06 ± 0.36                                    | 2.90 ± 0.30                                    | 0.662          | 0.985          |
| Day 1    |                                                 |                                                 |                                                 |                |                |
| SGPT/ALT | 49.13 ± 32.32                                  | 48.17 ± 30.59                                  | 28.40 ± 15.72                                  | 0.632          | 0.000          |
| SGOT/AST | 109.19 ± 49.39                                 | 93.65 ± 40.91                                  | 68.16 ± 38.11                                  | 0.207          | 0.094          |
| Serum LDH| 680.06 ± 511.08                                | 388.67 ± 172.73                                | 329.40 ± 157.54                                | 0.000          | 0.000          |
| ALP      | 350.75 ± 105.58                                | 338.11 ± 98.30                                 | 254.80 ± 98.43                                 | 0.727          | 0.455          |
| Total Protein | 5.29 ± 0.55                               | 5.31 ± 0.55                                    | 5.71 ± 0.40                                    | 0.706          | 0.030          |
| Serum albumin | 2.93 ± 0.60                                 | 3.07 ± 0.57                                    | 3.24 ± 0.40                                    | 0.873          | 0.034          |
| Total bilirubin | 5.00 ± 1.16                                 | 4.25 ± 1.74                                    | 3.45 ± 1.94                                    | 0.023          | 0.006          |
| Direct bilirubin | 1.19 ± 0.59                                 | 1.19 ± 0.70                                    | 1.10 ± 0.50                                    | 0.558          | 0.692          |
| PT       | 16.32 ± 1.62                                   | 15.40 ± 1.77                                    | 14.37 ± 1.74                                    | 0.521          | 0.676          |
| INR      | 1.15 ± 0.11                                   | 1.15 ± 0.11                                    | 1.13 ± 0.08                                    | 0.606          | 0.032          |
| Day 3    |                                                 |                                                 |                                                 |                |                |
| SGPT/ALT | 33.00 ± 14.00                                  | 31.44 ± 15.02                                  | 24.13 ± 8.15                                   | 0.865          | 0.078          |
| SGOT/AST | 60.69 ± 29.88                                  | 63.83 ± 24.57                                  | 51.87 ± 16.93                                  | 0.215          | 0.004          |
| Serum LDH| 1693.88 ± 515.28                               | 1060.70 ± 631.72                               | 322.33 ± 122.02                                | 0.997          | 0.000          |
| ALP      | 325.81 ± 79.00                                 | 283.26 ± 68.16                                  | 260.50 ± 74.76                                 | 0.238          | 0.568          |
| Total Protein | 5.56 ± 0.39                                 | 5.68 ± 0.41                                    | 5.81 ± 0.30                                    | 0.999          | 0.102          |
| Serum albumin | 3.06 ± 0.28                                 | 3.20 ± 0.45                                    | 3.36 ± 0.38                                    | 0.007          | 0.315          |
| Total bilirubin | 5.80 ± 1.70                                 | 5.99 ± 2.43                                    | 5.65 ± 3.07                                    | 0.016          | 0.01           |
| Direct bilirubin | 1.18 ± 0.50                                 | 1.52 ± 0.76                                    | 1.47 ± 0.74                                    | 0.057          | 0.05           |
| PT       | 15.80 ± 1.25                                   | 15.28 ± 1.50                                    | 14.38 ± 1.45                                    | 0.128          | 0.290          |
| INR      | 1.09 ± 0.07                                   | 1.12 ± 0.09                                    | 1.12 ± 0.09                                    | 0.358          | 0.793          |
| Day 10   |                                                 |                                                 |                                                 |                |                |
| SGPT/ALT | 25.81 ± 9.41                                   | 26.09 ± 7.9                                    | 23.47 ± 7.51                                   | 0.414          | 0.234          |
| SGOT/AST | 41.00 ± 13.28                                  | 40.96 ± 14.16                                  | 40.80 ± 10.80                                  | 0.679          | 0.171          |
| Serum LDH| 385.81 ± 94.18                                 | 348.69 ± 135.46                                | 271.90 ± 111.43                                | 0.024          | 0.391          |
| ALP      | 278.63 ± 71.14                                 | 271.39 ± 68.33                                 | 249.10 ± 77.10                                 | 0.846          | 0.746          |
| Total Protein | 5.73 ± 0.35                                 | 5.75 ± 0.44                                    | 5.81 ± 0.4122                                  | 0.203          | 0.521          |
| Serum albumin | 3.27 ± 0.39                                 | 3.36 ± 0.48                                    | 3.29 ± 0.39                                    | 0.122          | 0.752          |
| Total bilirubin | 3.03 ± 1.53                                 | 2.59 ± 1.38                                    | 2.25 ± 1.47                                    | 0.359          | 0.598          |
| Direct bilirubin | 1.21 ± 0.63                                 | 0.97 ± 0.72                                    | 0.7937 ± 0.58                                  | 0.764          | 0.693          |
| PT       | 14.66 ± 1.42                                   | 14.70 ± 1.78                                    | 13.920 ± 1.22                                  | 0.10           | 0.509          |
| INR      | 1.12 ± 0.09                                   | 1.12 ± 0.09                                    | 1.11 ± 0.05                                    | 0.746          | 0.001          |
| Mortality| 3                                              | 1                                              | 0                                              |               | 0.01           | 0.014          |

Table 1. Comparing the various liver function tests between newborns with severe asphyxia and moderate asphyxia, and severe asphyxia and normal neonates at age of first day, third day and tenth day.

and involves almost all organs of body in one way or other. The liver also exhibits different biochemical and histopathological changes secondary to asphyxia. Birth asphyxia in newborn infants can cause hepatic hypoxic injury, leading to release of intracellular enzymes and significant increase in their level.22,23 The aim of present study was to evaluate the severity and type of liver dysfunction in relation to Apgar score and HIE grading of asphyxiated neonates and also to determine the correlation with neonatal mortality.

We reported that in severely asphyxiated neonates on day 1, serum LDH and bilirubin can be used as markers to assess the severity of hepatic injury, whereas on day 3, decrease in serum albumin can be used. As liver injury will lead to decrease in synthetic function, leading to significant...
decrease in albumin level, whereas on day 10, serum LDH can be used to assess the degree of liver injury. Neonatal mortality is significantly increased in condition of asphyxia, where the newborns have five-minute Apgar score less than 3, which matches with the recent study published in *Lancet.*

Islam et al performed a prospective study of 70 full-term asphyxiated newborns. Venous blood was analyzed between second and fifth days of life to estimate serum AST, ALT, ALP, serum total bilirubin, serum total protein (STP), serum albumin, and PT. The mean AST, ALT, ALP, STP, serum albumin, and TSB of asphyxiated babies were 76.3 ± 37.4 U/L, 82.2 ± 48.08 U/L, 369.6 ± 123.05 U/L, 55.7 ± 8.8 U/L, 32.6 ± 5.5 g/L, and 5.5 ± 2.01 mg/dL, respectively, and those of normal babies were 23.5 ± 8.5 U/L, 26.5 ± 7.8 U/L, 208.2 ± 46.9 U/L, 66.3 ± 10.4 g/L, 40.9 ± 6.5 g/L, and 4.5 ± 1.2 mg/dL, respectively, and these differences were statistically significant (*P* < 0.001). On the other hand, no significant changes were noted in PT. The increase in AST, ALT, ALP, and PT also showed a significant positive correlation with the severity of asphyxia and the stages of HIE. This study showed that serum AST, ALT, and ALP increased more than the reference group, and the differences were statistically significant (*P* < 0.001). Limitation of this study was that they did not compared moderate and severe asphyxia neonates on...
basis of five-minute Apgar. We too noted significant increase in liver enzymes and showed the correlation between severity of hepatic derangement and Apgar score.

Karlsson et al conducted study to investigate the occurrence of hypoxic hepatitis in full-term infants after birth asphyxia and the temporal enzyme pattern in asphyxiated newborn infants. AST, ALT, LDH, gamma-glutamyl transferase, total and conjugated bilirubin, cholinesterase activity, albumin, INR, and nucleated red blood cell count were prospectively measured in 26 full-term asphyxiated newborns. Samples were collected three times during the first 72 hours and once between days 6 and 12 after birth. Fifty-six healthy newborns acted as control whose sample were collected 24–172 hours after birth. They reported increase in ALT, AST, and LDH in asphyxiated neonates and hence concluded that birth asphyxia can induce an enzyme pattern in serum compatible to hypoxic hepatitis. The results of the present study also showed increase in hepatic enzymes in asphyxiated neonates.

A recent published study by Karlsson et al assessed whether LDH, ALT, and AST during the first 12 hours after birth predict HIE and adverse neurodevelopment outcome in newborn term infants with intrapartum signs of fetal distress. The authors reported that a cutoff level of 1049 U/L for LDH was not only the best predictor of HIE (sensitivity 100% and specificity 97%) but was also useful for long-term outcome after HIE. The same findings were reported by Thoresen et al in which they predicted serum LDH as a novel biomarker, with a high negative predictive value in the assessment of outcome in therapeutic hypothermia-treated asphyxiated term infants. We too reported significant increase in serum LDH level in comparison to normal neonate, and the increase was more in neonates who had severe asphyxia in comparison to neonates with moderate asphyxia. In the present study, neurodevelopmental outcome was not seen in relation to Apgar score severity.

In another recent well-conducted study by Chhavi et al that sought serum liver enzyme pattern in birth asphyxia-associated liver injury, enrolled 60 controls and 62 cases singleton term newborns with birth asphyxia and ≤72 hours of age. Serum liver enzymes were measured at <24 hours, 24–72 hours, and at 6–12 days of age for cases and at 1–6 days of age for controls. They reported asphyxiated newborns had higher serum levels of ALT, AST, and LDH than the control infants, with peak at 24–72 hours followed by a sharp decline by 6–12 days of age. The results were similar to our study but there was no differentiation between moderate and severe asphyxia.

Sánchez-Nava et al conducted a study in 120 newborns, which were placed into two groups: group 1 of the asphyxiated neonates who were given oxygen at intermittent positive pressure for more than a minute and group 2 of healthy neonates with an Apgar greater than 7 after the first and five minutes and without any apparent pathology. Their results showed a real increase in level of all three transaminases (ALT, AST, and LDH) in the asphyxiated neonates, while on the other hand, this increase was not seen in the normal neonates. There were statistical differences between the two group by which they conclude that the quantification of these enzymes can be useful as a diagnostic tool in cases of perinatal asphyxia. These findings were comparable with our study results.

There are many other studies in asphyxiated neonates, which have studied hepatic dysfunction in asphyxiated neonates but we could not find any study that has correlated the hepatic dysfunction in moderately and severely asphyxiated neonates on the basis of five-minute Apgar score.

Limitation of the Study

- Number of infants having severe asphyxia was small (16 babies) that can make safe statistical conclusions difficult.
We took Apgar score criteria for labeling as asphyxia and we did not include all criteria of AAP for labeling them as perinatal asphyxia

Long-term neurodevelopmental outcome was not assessed to see the correlation between severity of hepatic dysfunction and neurodevelopmental outcome.

Elevation of transaminases may have been influenced by use of drugs such as phenobarbital or phenytoin in some patients, which was not differentiated.

No correlation of markers of hepatic health was seen with other markers of stress in patients such as acidosis, ventila

Conclusion

In perinatal asphyxia, multiple organ systems are damaged secondary to birth asphyxia in neonates, which includes hepatic, renal, hematological, pulmonary, cardiovascular, and nervous systems. The hepatic injury may represent a useful marker for assessment of severity of degree of asphyxial injury (when the neurologic examination is unreliable or misleading). Liver dysfunction in asphyxiated neonates is significant problem and is usually seen in majority of the cases. Hepatic dysfunction in majority of neonates manifest as raised hepatic enzymes, including AST, ALT, LDH, and bilirubin. The severity of dysfunction correlates well with increasing severity of asphyxia and correlates well with poor Apgar score, although we need to do a large multicentric trial to confirm our observations. Apgar score combined with hepatic dysfunction can be used as a prognostication marker for neonatal mortality in infants with severe asphyxia. We should keep a high index of suspicion of hepatic dysfunction in asphyxiated newborn, and all the asphyxiated neonates should be routinely screened for hepatic impairment. Biochemical parameters although, normalized on follow-up, the subtle parenchymal damage and alterations at molecular level may affect liver functions in future life, which require continuous long-term follow-up of these neonates for both hepatic and neurodevelopmental outcomes.

Abbreviations

HIE, hypoxic-ischemic encephalopathy
INR, International Normalized Ratio
AST, aspartate transferase
ALT, alanine transferase
ALP, alkaline phosphate
LDH, lactate dehydrogenase

Author Contributions

Conceived and designed the experiments: MC, DS. Analyzed the data: DS, SS. Wrote the first draft of the manuscript: MC, DS. Contributed to the writing of the manuscript: ML, SS. Agree with manuscript results and conclusions: MC, DS, ML, SS. Jointly developed the structure and arguments for the paper: SS. Made critical revisions and approved final version: MC, DS, ML, SS. All authors reviewed and approved of the final manuscript.

REFERENCES

1. Wang H, Liddell CA, Coates MM, et al. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9954):975–97.
2. Sharma D, Shastri S. Lactoferin and neonatology – role in neonatal sepsis and necrotizing enterocolitis: present, past and future. J Matern Fetal Neonatal Med. 2016;29(9):763–70.
3. Sharma D, Pandita A, Kumar C. Lactoferin and neonates: role in prevention of neonatal sepsis and necrotizing enterocolitis. J Neonatal Biol. 2014;35(5):1000E–110E.
4. Sharma D, Murki A, Murki S, Pratap OT. Use of lactoferin in the newborn: where do we stand? J Matern Fetal Neonatal Med. 2014;9:1–5.
5. Pandita A, Sharma D, Kumar C. Lactoferin and its role in neonatology: a review article. J Pediatr Neonatal Care. 2015;20(2):00062. doi: 10.15406/npnc.2015.02.00062.
6. Gathwala G, Sharma D, Bakhri BK. Effect of topical application of chlorhexidine for umbilical cord care in comparison with conventional dry cord care on the risk of neonatal sepsis: a randomized controlled trial. J Trop Pediatr. 2009;55(3):209–13.
7. Gupta B, Yawwani ND, Sharma D, Chaudhary U, Lekhwani S. Evaluation of efficacy of skin cleansing with chlorhexidine in prevention of neonatal nosocomial sepsis – a randomized controlled trial. J Matern Fetal Neonatal Med. 2014:8:1–26.
8. Sharma D, Gathwala G. Impact of chlorhexidine cleansing of the umbilical cord on cord separation time and neonatal mortality in comparison to dry cord care – a nursery-based randomized controlled trial. J Matern Fetal Neonatal Med. 2014;24(7):1262–5.
9. Sharma DK, Gathwala G, Shastri S. Chlorhexidine – a novel intervention to decrease the nursery stay and antibiotic exposure duration-randomized trial. J Matern Fetal Neonatal Med. 2014;1:1–21.
10. Lawn JE, Kerber K, Ewenrother-Laryea C, Massie Bateman O. Neonatal survival in low resource settings – are we delivering? BJOG. 2009;116(suppl):1:49–59.
11. Lawn JE, Coussens S, Zupon J. Lancer Neonatal Survival Steering Team. 4 million neonatal deaths: where? Where? Why? Lancet. 2005;365(9462):891–900.
12. Sharma D, Shastri S, Farahbaksh N, Sharma P. Intrauterine growth restriction – part 1. J Matern Fetal Neonatal Med. 2016;71:1–11.
13. Sharma D, Farahbaksh N, Shastri S, Sharma P. Intrauterine growth restriction – part 2. J Matern Fetal Neonatal Med. 2016;15:1–12.
14. Murki S, Sharma D. Intrauterine growth retardation – a review article. J Neonatal Biol. 2014;3:135.
15. Aza Haider B, Bhutta ZA. Birth asphyxia in developing countries: current status and public health implications. Curr Probl Pediatr Adolesc Health Care. 2006;36(5): 178–88.
16. Lamba M, Sharma R, Sharma D, Caudhary M, Maheshwari RK. Bacteriological spectrum and antimicrobial susceptibility pattern of neonatal septicaemia in a tertiary care hospital of North India. J Matern Fetal Neonatal Med. 2016;3:1–6.
17. Sharma D, Kumar C, Pandita A, Pratap OT, Dasi T, Murki S. Bacteriological profile and clinical predictors of ESBL neonatal sepsis. J Matern Fetal Neonatal Med. 2016;29(4):567–70.
18. Laxtan R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.
19. Ensing S, Abu-Hanna A, Schaaf JM, Mol BWJ, Ravelli ACJ. Trends in birth asphyxia, obstetric interventions and perinatal mortality among term singletons: a nationwide cohort study. J Matern Fetal Neonatal Med. 2014;0:1–6.
20. Ghasirambania P, Sharma D, Patel A, Shastri S. To study the incidence, etiology and ECG profile of neonatal seizures: a prospective observational study from India. J Matern Fetal Neonatal Med. 2016;26(4):354–8.
21. Patel A, Sharma D, Shastri S, Sharma P. Acute renal failure in critically ill newborns increases the risk of death: a prospective observational study from India. J Matern Fetal Neonatal Med. 2015;2:1–5.
22. Shah P, Riphagen S, Beyej N, Perlman M. Multiorgan dysfunction in infants with post-asphyxial hypoxic–ischemic encephalopathy. Arch Dis Child Fetal Neonatal Ed. 2004;89(2):P152–5.
23. Shah PS, Perlman M. Time courses of intrapartum asphyxia: neonatal characteristics and outcomes. Am J Perinatol. 2009;26(1):39–44.
24. Phelan JP, Ahn MO, Korsel L, Martin GI, Wang YM. Intrapartum fetal asphyxial brain injury with absent multiorgan system dysfunction. J Matern Fetal Med. 1997;7(1):19–22.
25. Beharier O, Kahn J, Shusterman E, Shiner E. S100B – a potential biomarker for early detection of neonatal brain damage following asphyxia. J Matern Fetal Neonatal Med. 2012;25(9):1523–8.
26. Committee on Fetus and Newborn, American Academy of Pediatrics, Committee on Obstetric Practice, American College of Obsetricians and Gynecologists. Use and abuse of the Apgar score. Pediatrics. 1996;98(1):141–2.
27. Hansen AR, Soul JS. Perinatal asphyxia and hypoxic ischemic encephalopathy. In: Cloherty JP, Eichenwald EC, Hansen AR, Stark AR, eds. Manual of Neonatal Care. Seventh ed. Philadelphia: Lippincott Williams and Wilkins; 2011:711–28.
28. Fekete M, Borykai A, Kluiber L. Perinatal hypoxia and hepatic cell function in preterm and full term newborn infants. *Acta Paediatr Hung.* 1987;28(1):23–8.
29. Biodromini S, Mackay DF, Smith GCS, Pelt JP; Nelson SM. Apgar score and the risk of cause-specific infant mortality: a population-based cohort study. *Lancet.* 2014;384(9956):1749–55.
30. Fekete M, Botykai A, Klujber L. Perinatal hypoxia and hepatic cell function in preterm and full term newborn infants. *Acta Paediatr Hung.* 1987;28(1):23–8.
31. Iliodromiti S, Mackay DF, Smith GCS, Pell JP, Nelson SM. Apgar score and the risk of cause-specific infant mortality: a population-based cohort study. *Clin Med Insights Pediatr.* 2015;9:1–6.
32. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. *Arch Neurol.* 1976;33(10):696–705.
33. Sharma D, Pandita A, Shastri S. Neonatal hypertension: an underdiagnosed condition, a review article. *Curr Hypertens Rev.* 2014;10(4):205–12.
34. Islam MT, Islam MN, Mollah AH, et al. Status of liver enzymes in babies with perinatal asphyxia. *Mymensingh Med J.* 2011;20(3):446–9.
35. Karlsson M, Blennow M, Nemeth A, Winbladh B. Dynamics of hepatic enzyme activity following birth asphyxia. *Acta Paediatr.* 2006;95(11):1405–11.
36. Thoresen M, Liu X, Jary S, et al. Lactate dehydrogenase in hypothermia-treated newborn infants with hypoxic-ischaemic encephalopathy. *Acta Paediatr.* 2010;99(8):1139–44.
37. Chhavi N, Zutshi K, Singh NK, Awashti A, Goel A. Serum liver enzyme pattern in birth asphyxia associated liver injury. *Pediatr Gastroenterol Hepatol Nutr.* 2014;17(3):162–9.
38. Sánchez-Nava J, González-Carreño S, Hernández-Martínez JA, Pezzotti Y, Rentería MA. Increase in glutamic-oxaloacetic and glutamic-pyruvic transaminases and lactic dehydrogenase as a diagnostic aid in perinatal asphyxia. *Biol Med Hosp Infant Mex.* 1990;47(6):372–5.
39. Reddy S, Dutta S, Narang A. Evaluation of lactate dehydrogenase, creatine kinase and hepatic enzymes for the retrospective diagnosis of perinatal asphyxia among sick neonates. *Indian Pediatr.* 2008;45(2):144–7.
40. Tarcan A, Tiker F, Güvenir H, Gürkan B. Hepatic involvement in perinatal asphyxia. *J Matern Fetal Neonatal Med.* 2007;20(5):407–10.
41. Elbim SF, Uslan RH, Molk S, Kandalkar BM. Hepatic profile in asphyxiated neonates. *Indian Pediatr.* 1997;34(10):927–30.
42. Barberi I, Calabrò MP, Cordaro S, et al. Myocardial ischaemia in neonates with perinatal asphyxia. Electrocardiographic, echocardiographic and enzymatic correlations. *Eur J Pediatr.* 1999;158(9):742–7.
43. Lackmann GM, Töllner U. The predictive value of elevation in specific serum enzymes for subsequent development of hypoxic-ischemic encephalopathy or intraventricular hemorrhage in full-term and premature asphyxiated newborns. *Neuropediatrics.* 1995;26(4):192–8.
44. Esqué-Ruiz MT, Figueras-Aloy J, Salvia-Roigés MD, Carbonell-Estrany X. [Blood ammonia and transaminases in full term infants suffering from perinatal asphyxia]. *Rev Neurol.* 2003;36(9):801–5.
45. Salli A, Sarna MS, Gathwala G, Kumari S, Dutta AK. Liver dysfunction in severe birth asphyxia. *Indian Pediatr.* 1990;27(12):1291–4.
46. Goldberg RN, Cabal LA, Sinatra FR, Plasnick CE, Hodgman JE. Hyperammonemia associated with perinatal asphyxia. *Pediatrics.* 1979;64(3):336–41.
47. Salonvaara M, Rikonen P, Kekomäki R, et al. Effects of gestational age and prenatal and perinatal events on the coagulation status in premature infants. *Arch Dis Child Fetal Neonatal Ed.* 2003;88(4):F319–23.